Silver Book Fact

Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.

Harris S, Watts N, Genant H, McKeever C, et al. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: A randomized controlled trial. JAMA. 1999; 282(14): 1344-52. http://jama.ama-assn.org/cgi/content/abstract/282/14/1344

Reference

Title
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: A randomized controlled trial
Publication
JAMA
Publication Date
1999
Authors
Harris S, Watts N, Genant H, McKeever C, et al.
Volume & Issue
Volume 282, Issue 14
Pages
1344-52
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.  
  • Reducing secondary bone fractures can reduce medicare spending
    Reducing 5-20 percent of “secondary” bone fractures in 2015 could have reduced Medicare FFS spending by $310 million to $1.2 billion over a follow-up period that lasted up to 2 to…  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.